VanEck Vectors Biotech ETF (BBH) Stock
NMQ · BBH
244.76
Fundamentals
Market cap
$466.04M
Price / Earnings ratio
0.0x
Price / Sales ratio
N/A
Price / Book ratio
N/A
Return on assets
N/A
Ex-Dividend date
N/A
Last payment date
26 Dec 2025
Dividend amount
N/A
Dividend yield
0.39%
Debt / Equity ratio
N/A
Recent news

The Motley Fool
Fidelity Healthcare ETF (FHLC) vs. VanEck Biotech ETF (BBH): Which Fund Is the Better Buy?
NeutralBBHSeptember 24, 2026
The Motley FoolNeutral
Fidelity Healthcare ETF (FHLC) vs. VanEck Biotech ETF (BBH): Which Fund Is the Better Buy?
BBH

Zacks Investment Research
Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate
NeutralBBHSeptember 21, 2026
Zacks Investment ResearchNeutral
Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate
BBH

Reuters
Retension Pharmaceuticals, TRex Bio file for US IPO as biotech momentum continues
NeutralBBHSeptember 18, 2026
ReutersNeutral
Retension Pharmaceuticals, TRex Bio file for US IPO as biotech momentum continues
BBH

Zacks Investment Research
Should You Invest in the VanEck Biotech ETF (BBH)?
NeutralBBHSeptember 16, 2026
Zacks Investment ResearchNeutral
Should You Invest in the VanEck Biotech ETF (BBH)?
BBH
Technicals
OscillatorsBuy5 Indicators
Moving AveragesStrong Buy12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy0
Strong Buy0
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

The Motley Fool
Fidelity Healthcare ETF (FHLC) vs. VanEck Biotech ETF (BBH): Which Fund Is the Better Buy?
NeutralBBHSeptember 24, 2026
The Motley FoolNeutral
Fidelity Healthcare ETF (FHLC) vs. VanEck Biotech ETF (BBH): Which Fund Is the Better Buy?
BBH

Zacks Investment Research
Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate
NeutralBBHSeptember 21, 2026
Zacks Investment ResearchNeutral
Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate
BBH

Reuters
Retension Pharmaceuticals, TRex Bio file for US IPO as biotech momentum continues
NeutralBBHSeptember 18, 2026
ReutersNeutral
Retension Pharmaceuticals, TRex Bio file for US IPO as biotech momentum continues
BBH

Zacks Investment Research
Should You Invest in the VanEck Biotech ETF (BBH)?
NeutralBBHSeptember 16, 2026
Zacks Investment ResearchNeutral
Should You Invest in the VanEck Biotech ETF (BBH)?
BBH

The Motley Fool
State Street XLV vs VanEck BBH: Which Healthcare ETF Is the Better Buy in 2026?
NeutralBBHAugust 5, 2026
The Motley FoolNeutral
State Street XLV vs VanEck BBH: Which Healthcare ETF Is the Better Buy in 2026?
BBH

The Motley Fool
IHE vs. BBH: Which Healthcare ETF Is the Better Buy Right Now?
NeutralBBHJuly 19, 2026
The Motley FoolNeutral
IHE vs. BBH: Which Healthcare ETF Is the Better Buy Right Now?
BBH

The Motley Fool
Invesco Healthcare ETF vs VanEck Biotech: Which ETF Will Deliver the Healthiest Returns for 2026?
NeutralBBHJuly 14, 2026
The Motley FoolNeutral
Invesco Healthcare ETF vs VanEck Biotech: Which ETF Will Deliver the Healthiest Returns for 2026?
BBH

Zacks Investment Research
Should You Invest in the VanEck Biotech ETF (BBH)?
NeutralBBHJuly 13, 2026
Zacks Investment ResearchNeutral
Should You Invest in the VanEck Biotech ETF (BBH)?
BBH

The Motley Fool
Which is the Better Choice for Healthcare Investors? IYH or BBH?
NeutralBBHJuly 11, 2026
The Motley FoolNeutral
Which is the Better Choice for Healthcare Investors? IYH or BBH?
BBH

The Motley Fool
BBH vs. XPH: Which Healthcare ETF Is Better for Beginners?
NeutralBBHJuly 8, 2026
The Motley FoolNeutral
BBH vs. XPH: Which Healthcare ETF Is Better for Beginners?
BBH
About VanEck Vectors Biotech ETF
VanEck Vectors® Biotech ETF (BBH) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Biotech 25 Index, which is intended to track the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment.
Fundamentals
Valuation
Market cap$466.04M
Price-to-sales ratioN/A
Price-to-book valueN/A
Price-earnings ratio0.00
Return on EquityN/A
Return on SalesN/A
Return on AssetsN/A
PEG ratioN/A
Earnings Per Share
Earnings Per ShareN/A
Income Statement
Average volume11,497
EBITDAN/A
1 year high (52w)$244.35
1 year low (52w)$160.91
Dividend
Ex dividend dateN/A
Dividend amountN/A
Dividend yield0.39%
Last payment date26 Dec 2025
Dividend yield (TTM)0.39%
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsBuy5 Indicators
Moving AveragesStrong Buy12 Indicators
What the experts say
0 Wall Street Analyst Ratings
N/A
0% Buy
0% Hold
0% Sell
Target price
$0.00
Est return
0.00%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +0.3 | +1.5 | -2.7 | -0.8 | ||||||||
| 2022 | -11.6 | -6.5 | +4.1 | -11.8 | -0.4 | -0.3 | +3.5 | -4.3 | -4.8 | +9.6 | +6.4 | -5.7 |
| 2023 | +5.8 | -6.9 | +2.8 | -1.4 | -3.8 | +0.6 | +3.2 | +2.8 | -5.6 | -6.5 | +3.5 | +7.6 |
| 2024 | -2.3 | -2.7 | +0.3 | -6.0 | +3.8 | +1.2 | +7.1 | -0.1 | -0.5 | -3.9 | -2.0 | -5.9 |
| 2025 | +5.2 | -0.5 | -3.2 | -0.9 | -1.1 | +2.6 | +4.2 | +1.6 | -0.4 | +5.2 | +9.9 | -2.6 |
| 2026 | +3.4 | +0.4 | -4.2 | -2.1 | +3.0 | +9.3 | +0.5 | +15.7 | +2.5 |
Corporate actions
Upcoming
No upcoming corporate actions for BBH
Past
DividendQ4/25
Ex-dividend date22 Dec 2025
Payable date26 Dec 2025
Amount per share$0.96
DividendQ4/24
Ex-dividend date23 Dec 2024
Payable date24 Dec 2024
Amount per share$1.25
DividendQ4/22
Ex-dividend date19 Dec 2022
Payable date23 Dec 2022
Amount per share$0.75
DividendQ4/21
Ex-dividend date20 Dec 2021
Payable date27 Dec 2021
Amount per share$0.40



